Skip to main content
ConductScienceScienceDex

Bellail, Anita

From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.

FY2023 NIH rank #6,773
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2018 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

FY2023 award categories

  • Pathology

NIH Funding · FY2023

Linked Award Amount
$1.4M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#6,773
By linked amount among FY2023 PIs
Earliest Year Loaded
2018
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Bellail, Anita. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2023 award records by amount

NIH award records listing Bellail, Anita as a PI. Multi-PI records show the full award amount for context.

  • 5R44CA265547-02R44Contact PI
    Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer
    Hb Therapeutics, Inc.
    $979.5K
    award amount
  • 5R01CA266699-02R01Contact PI
    Targeting SUMO1 degradation for advanced colon cancer therapy
    Indiana University Indianapolis · Pathology (NIH department code)
    $374K
    award amount

Award organizations

Organizations that administered FY2023 awards listing Bellail, Anita as a PI.

Hb Therapeutics, Inc.
$979.5K
1 grant
Indiana University Indianapolis
IN
$374K
1 grant

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2018
    First NIH Award
    Hb Therapeutics, Inc.
  2. 2022
    $500K Cumulative Funding
  3. 2022
    $1M Cumulative Funding
  4. 2022
    Entered Top 50% Nationally
    Ranked #6315
  5. 2022
    Multi-Institutional Research
    Awards at 2 institutions
  6. 2022
    R01 Grant Holder
  7. 2023
    $2M Cumulative Funding

Explore further

Find collaborators for Bellail, Anita

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →